[Chemotherapy for Malignancy During Pregnancy - Literature Review.]

Area of Science:

• Oncology
• Maternal-Fetal Medicine
• Obstetrics

Background:

• Malignant diseases during pregnancy are increasingly common.
• Therapeutic decisions are complex due to risks to both mother and fetus.
• Standardized treatment algorithms are lacking.

Purpose of the Study:

• To review the benefits and risks of treating malignant diseases during pregnancy.
• To analyze the impact of gestational timing on treatment outcomes.
• To provide insights into managing cancer in pregnant patients.

Main Methods:

• Literature review of studies on cancer treatment in pregnancy.
• Analysis of risks and benefits based on gestational period.
• Examination of chemotherapy timing and its implications.

Main Results:

• Chemotherapy is generally avoided before 10-12 weeks of gestation.
• The optimal timing for the last chemotherapy course is around the 35th week of gestation or three weeks before the due date.
• Treatment decisions must balance maternal health and fetal safety.

Conclusions:

• Managing malignant diseases during pregnancy requires careful consideration of gestational age.
• Individualized treatment plans are crucial for optimizing outcomes for both mother and child.
• Further research into standardized protocols is warranted.